ANN LEEN to Humans
This is a "connection" page, showing publications ANN LEEN has written about Humans.
Connection Strength
0.699
-
Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia. Blood. 2024 04 25; 143(17):1726-1737.
Score: 0.025
-
Longitudinal analysis of the evolution of cellular immunity to SARS-CoV-2 induced by infection and vaccination. Haematologica. 2023 Jul 01; 108(7):1934-1939.
Score: 0.024
-
Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand-Expressing Solid Tumors. Cancer Immunol Res. 2022 11 02; 10(11):1370-1385.
Score: 0.022
-
Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597.
Score: 0.020
-
The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. Sci Transl Med. 2020 07 29; 12(554).
Score: 0.019
-
Toward Functional Immune Monitoring in Allogeneic Stem Cell Transplant Recipients. Biol Blood Marrow Transplant. 2020 05; 26(5):911-919.
Score: 0.018
-
Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections. Haematologica. 2020 01; 105(1):235-243.
Score: 0.018
-
Infusion of cytotoxic T lymphocytes for the treatment of viral infections in hematopoetic stem cell transplant patients. Curr Opin Infect Dis. 2018 08; 31(4):292-300.
Score: 0.017
-
Dynamics of virus-specific T cell immunity in pediatric liver transplant recipients. Am J Transplant. 2018 09; 18(9):2238-2249.
Score: 0.017
-
Immunologic Profiling of Human Metapneumovirus for the Development of Targeted Immunotherapy. J Infect Dis. 2017 09 15; 216(6):678-687.
Score: 0.016
-
Characterizing the Cellular Immune Response to Parainfluenza Virus 3. J Infect Dis. 2017 07 15; 216(2):153-161.
Score: 0.016
-
Preventing stem cell transplantation-associated viral infections using T-cell therapy. Immunotherapy. 2015; 7(7):793-810.
Score: 0.014
-
Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014 Jun 25; 6(242):242ra83.
Score: 0.013
-
Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther. 2014 Jun; 22(6):1211-1220.
Score: 0.012
-
Antiviral T-cell therapy. Immunol Rev. 2014 Mar; 258(1):12-29.
Score: 0.012
-
Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013 Nov; 21(11):2113-21.
Score: 0.012
-
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013 Jun 27; 121(26):5113-23.
Score: 0.012
-
T-cell therapy for viral infections. Hematology Am Soc Hematol Educ Program. 2013; 2013:342-7.
Score: 0.011
-
Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood. 2013 Jan 03; 121(1):207-18.
Score: 0.011
-
Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther. 2012 Aug; 20(8):1622-32.
Score: 0.011
-
Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther. 2011 Dec; 19(12):2258-68.
Score: 0.010
-
Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant. J Vis Exp. 2011 May 27; (51).
Score: 0.010
-
T-cell therapy: the next generation. Expert Rev Hematol. 2010 Apr; 3(2):123-5.
Score: 0.009
-
Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert Opin Biol Ther. 2010 Mar; 10(3):337-51.
Score: 0.009
-
Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009 Nov 05; 114(19):4283-92.
Score: 0.009
-
Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther. 2009 Sep; 17(9):1616-25.
Score: 0.009
-
Cytotoxic T lymphocytes as immune-therapy in haematological practice. Br J Haematol. 2008 Oct; 143(2):169-79.
Score: 0.008
-
Using dendritic cell maturation and IL-12 producing capacity as markers of function: a cautionary tale. J Immunother. 2008 May; 31(4):359-69.
Score: 0.008
-
Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol. 2008 Jan; 82(1):546-54.
Score: 0.008
-
Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun; 39(11):677-86.
Score: 0.008
-
Improving T cell therapy for cancer. Annu Rev Immunol. 2007; 25:243-65.
Score: 0.007
-
Contact-activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells. J Immunother. 2007 Jan; 30(1):96-107.
Score: 0.007
-
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006 Oct; 12(10):1160-6.
Score: 0.007
-
Adenoviral infections in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006 Mar; 12(3):243-51.
Score: 0.007
-
T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients. Ann N Y Acad Sci. 2005 Dec; 1062:104-15.
Score: 0.007
-
Molecular dynamics at immune synapse lipid rafts influence the cytolytic behavior of CAR T cells. Sci Adv. 2025 Jan 10; 11(2):eadq8114.
Score: 0.007
-
Adenovirus as an emerging pathogen in immunocompromised patients. Br J Haematol. 2005 Jan; 128(2):135-44.
Score: 0.007
-
Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients. Blood Adv. 2024 09 10; 8(17):4740-4750.
Score: 0.006
-
Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood. 2004 Oct 15; 104(8):2432-40.
Score: 0.006
-
LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study. Lancet Oncol. 2024 Apr; 25(4):488-500.
Score: 0.006
-
Phenotypic and functional characterization of posoleucel, a multivirus-specific T cell therapy for the treatment and prevention of viral infections in immunocompromised patients. Cytotherapy. 2024 Aug; 26(8):869-877.
Score: 0.006
-
Incongruity between T cell receptor recognition of breast cancer hotspot mutations ESR1 Y537S and D538G following exogenous peptide loading versus endogenous antigen processing. Cytotherapy. 2024 03; 26(3):266-275.
Score: 0.006
-
Assessment of the cytolytic potential of a multivirus-targeted T cell therapy using a vital dye-based, flow cytometric assay. Front Immunol. 2023; 14:1299512.
Score: 0.006
-
Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood. 2004 Feb 01; 103(3):1011-9.
Score: 0.006
-
Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2-Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised Patients. Clin Infect Dis. 2023 09 11; 77(5):696-702.
Score: 0.006
-
Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients. Haematologica. 2023 Jul 01; 108(7):1840-1850.
Score: 0.006
-
T cell immune profiling of respiratory syncytial virus for the development of a targeted immunotherapy. Br J Haematol. 2023 08; 202(4):874-878.
Score: 0.006
-
Cord blood transplantation for nonmalignant disorders: early functional immunity and high survival. Blood Adv. 2023 05 09; 7(9):1823-1830.
Score: 0.006
-
Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting. Clin Cancer Res. 2023 01 17; 29(2):324-330.
Score: 0.006
-
Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant?in patients with ALL. Blood. 2022 04 28; 139(17):2706-2711.
Score: 0.005
-
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. J Immunother Cancer. 2021 11; 9(11).
Score: 0.005
-
Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol. 2001 Sep; 75(18):8649-59.
Score: 0.005
-
T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425.
Score: 0.005
-
Identification of protective T-cell antigens for smallpox vaccines. Cytotherapy. 2020 11; 22(11):642-652.
Score: 0.005
-
Evaluation of cyclin A1-specific T cells as a potential treatment for acute myeloid leukemia. Blood Adv. 2020 Jan 28; 4(2):387-397.
Score: 0.005
-
Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity. J Immunother Cancer. 2019 11 28; 7(1):330.
Score: 0.005
-
Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy. Cytotherapy. 2019 02; 21(2):212-223.
Score: 0.004
-
Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discov. 2018 08; 8(8):972-987.
Score: 0.004
-
CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer. 2018 05 10; 6(1):34.
Score: 0.004
-
Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 01; 35(31):3547-3557.
Score: 0.004
-
Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells. Clin Cancer Res. 2017 Jul 15; 23(14):3499-3509.
Score: 0.004
-
Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Mol Ther. 2017 01 04; 25(1):249-258.
Score: 0.004
-
Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol. 2016 05; 137(5):1498-1505.e1.
Score: 0.004
-
General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1284-90.
Score: 0.003
-
Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells. Mol Ther. 2015 Jan; 23(1):179-83.
Score: 0.003
-
Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity. J Immunother. 2014 May; 37(4):193-203.
Score: 0.003
-
Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood. 2014 Jun 19; 123(25):3895-905.
Score: 0.003
-
Systemic inflammatory response syndrome after administration of unmodified T lymphocytes. Mol Ther. 2014 Jun; 22(6):1134-1138.
Score: 0.003
-
T lymphocytes targeting native receptors. Immunol Rev. 2014 Jan; 257(1):39-55.
Score: 0.003
-
Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther. 2014 Mar; 22(3):623-633.
Score: 0.003
-
Engineered T cells for cancer treatment. Cytotherapy. 2014 Jun; 16(6):713-33.
Score: 0.003
-
Is cancer gene therapy an empty suit? Lancet Oncol. 2013 Oct; 14(11):e447-e456.
Score: 0.003
-
Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy. Clin Cancer Res. 2013 Sep 15; 19(18):5079-91.
Score: 0.003
-
Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. Leukemia. 2013 Jul; 27(7):1538-47.
Score: 0.003
-
Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2013 Jun; 16(2):123-31, S1.
Score: 0.003
-
Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. J Immunother. 2013 Jan; 36(1):66-76.
Score: 0.003
-
Enhancing immune reconstitution: from bench to bedside. Biol Blood Marrow Transplant. 2013 Jan; 19(1 Suppl):S79-83.
Score: 0.003
-
T-cell therapy: a powerful tool for the management of viral infections and relapse post hematopoietic stem cell transplantation. Expert Rev Hematol. 2012 Oct; 5(5):471-3.
Score: 0.003
-
Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res. 2012 Apr 01; 72(7):1621-31.
Score: 0.003
-
Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother. 2012 Feb-Mar; 35(2):159-68.
Score: 0.003
-
Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant. Cytotherapy. 2012 Jan; 14(1):7-11.
Score: 0.003
-
Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin Cancer Res. 2011 Nov 15; 17(22):7058-66.
Score: 0.003
-
Evaluation and management of BK virus-associated nephropathy following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011 Nov; 17(11):1589-93.
Score: 0.003
-
Engineered T cells for pancreatic cancer treatment. HPB (Oxford). 2011 Sep; 13(9):643-50.
Score: 0.003
-
PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther. 2011 Dec; 19(12):2133-43.
Score: 0.003
-
Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma. Cytotherapy. 2011 May; 13(5):518-22.
Score: 0.002
-
High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood. 2011 Mar 24; 117(12):3353-62.
Score: 0.002
-
Improved antibiotic-free plasmid vector design by incorporation of transient expression enhancers. Gene Ther. 2011 Apr; 18(4):334-43.
Score: 0.002
-
How I treat adenovirus in hematopoietic stem cell transplant recipients. Blood. 2010 Dec 16; 116(25):5476-85.
Score: 0.002
-
Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010 Nov 25; 116(22):4700-2.
Score: 0.002
-
Absence of systemic immune response to adenovectors after intraocular administration to children with retinoblastoma. Mol Ther. 2010 Oct; 18(10):1885-90.
Score: 0.002
-
Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. Leuk Lymphoma. 2010 May; 51(5):870-80.
Score: 0.002
-
Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother. 2010 Apr; 33(3):305-15.
Score: 0.002
-
Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood. 2010 Apr 01; 115(13):2695-703.
Score: 0.002
-
Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes. J Immunother. 2009 Sep; 32(7):726-36.
Score: 0.002
-
Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009 Aug 27; 114(9):1958-67.
Score: 0.002
-
Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther. 2009 May; 17(5):880-8.
Score: 0.002
-
Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother. 2008 Sep; 31(7):665-74.
Score: 0.002
-
Progress and prospects: gene therapy clinical trials (part 2). Gene Ther. 2007 Nov; 14(22):1555-63.
Score: 0.002
-
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007 Oct 15; 110(8):2838-45.
Score: 0.002
-
Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12. J Immunother. 2007 Jul-Aug; 30(5):506-16.
Score: 0.002
-
Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J Immunol. 2005 Sep 15; 175(6):4137-47.
Score: 0.002
-
CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J Virol. 2005 Apr; 79(8):4896-907.
Score: 0.002
-
The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother. 2004 Jul-Aug; 27(4):317-27.
Score: 0.002
-
Adoptive immunotherapy for posttransplantation viral infections. Biol Blood Marrow Transplant. 2004 Mar; 10(3):143-55.
Score: 0.002
-
Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. Int J Cancer. 2002 May 01; 99(1):93-9.
Score: 0.001